Choosing first-line therapy for chronic lymphocytic leukemia.
about
Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metforminPolymer nanoparticulate drug delivery and combination cancer therapy.Recent advances in therapy of chronic lymphocytic leukaemia.Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
P2860
Choosing first-line therapy for chronic lymphocytic leukemia.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Choosing first-line therapy for chronic lymphocytic leukemia.
@ast
Choosing first-line therapy for chronic lymphocytic leukemia.
@en
type
label
Choosing first-line therapy for chronic lymphocytic leukemia.
@ast
Choosing first-line therapy for chronic lymphocytic leukemia.
@en
prefLabel
Choosing first-line therapy for chronic lymphocytic leukemia.
@ast
Choosing first-line therapy for chronic lymphocytic leukemia.
@en
P2860
P356
P1476
Choosing first-line therapy for chronic lymphocytic leukemia
@en
P2093
Jeffrey A Jones
P2860
P304
P356
10.1586/ERA.11.132
P577
2011-09-01T00:00:00Z